Hepatitis D

Infectious Disease·MeSH: Hepatitis D

Prevalence

30.0 / 100K

11 drugs in development·6 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
brelovitug	Mirum Pharmaceuticals, Inc. (MIRM)
bulevirtide	Mirum Pharmaceuticals, Inc. (MIRM)
delayed treatment with brelovitug	Mirum Pharmaceuticals, Inc. (MIRM)
libevitug	China Health Industries Holdings, Inc. (CHHE)
peginterferon lambda	Eiger BioPharmaceuticals, Inc. (EIGR)

Phase 2(3)

Drug	Company
hh-003	China Health Industries Holdings, Inc. (CHHE)
taf	China Health Industries Holdings, Inc. (CHHE)
Tobevibart	Xencor Inc (XNCR)

Phase 1(1)

Drug	Company
abi-6250	ASSEMBLY BIOSCIENCES, INC. (ASMB)

Preclinical(1)

Drug	Company
ABI-6250 (6250)	ASSEMBLY BIOSCIENCES, INC. (ASMB)

BLA Filed(1)

Drug	Company
bulevirtide	GILEAD SCIENCES, INC. (GILD)

BioSniper tracks 11 drugs in development for Hepatitis D across 6 companies.

There are 1 clinical trial targeting Hepatitis D tracked by BioSniper.

The estimated prevalence of Hepatitis D is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.